Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim
A S
AS
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. akesselheim@partners.org
D000890:Anti-Infective Agents / Q000191:economics; D023482:Bioterrorism / Q000517:prevention & control; D003140:Communicable Disease Control / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D017277:Drug Approval / Q000458:organization & administration; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D005380:Financing, Government / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D006292:Health Priorities / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D006801:Humans; D014481:United States; D014483:United States Dept. of Health and Human Services / Q000458:organization & administration; D014486:United States Food and Drug Administration / Q000458:organization & administration; D014612:Vaccines / Q000191:economics
D000890:Anti-Infective Agents; D014612:Vaccines